The employer Farmaindustria has presented the results of the survey on R&D activities that prepares every year among its associates.
The pharmaceutical industry settled in Spain invested 1,004 million euros in research and development projects during 2015, as reflected in the results of the survey on R&D activities that elaborates each year among its associates the employer of innovative laboratories, Farmaindustria.Together with these data, Farmaindustria points out that the pharmaceutical sector consolidates its leadership in industrial R&D in Spain.
More than one billion account for an increase of 5.7 percent compared to the 2014 figure (950 million euros), which represents the largest year -on -year increase in the last seven years.In addition, this increase maintains the positive trend that began in 2014, consolidating the strong commitment of the sector despite the hardness of the crisis and savings measures.Thus, in 2014 and 2015 it has increased by 2.4 percent and 5.7 percent, respectively.
Light staff rebound
In addition, the survey confirms that in 2015 there has been a slight rebound in the personnel used in R&D (1.1 percent more than in 2014), which constitutes a stable, diverse source of employment (approximately two thirds of those employed inThis field are women) and high qualification (86 percent are higher degrees).
It should be noted that 416 million euros were allocated to research contracts with hospitals, universities and research centers, which is called R&D.This item has been increased by almost 9 percent compared to 2014, and represents 41 percent of the total R&D investment of the pharmaceutical industry.This investment, which is essential for the investigation of new drugs and for the scientific development of organizations and health professionals, makes the pharmaceutical industry the main driver of biomedical public-private collaboration in our country, with an investment that, although led by Madrid and Catalonia, it is distributed by all autonomies.
Intramuros Research
Intramuros investigation reached 588 million euros, around 59 percent of total investment.The highest percentage of these investments was carried out in Madrid (47 percent) and in Catalonia (41 percent);The remaining 12 percent was carried out in other communities or abroad.
As for spending items invested in R&D, the main one was dedicated to clinical trials, with just over 495 million euros.It should be noted that the investment in this field has increased at an average annual rate of 4.3 percent in the last 10 years, from 324 million euros in 2005 to 495 million euros in 2015.
From this item dedicated to clinical trials, about 37 percent is invested in investigations in phase I and Phase II, that is, the phases that generate greater added value.Since 2005, when the early phases were 25.6 percent of the total, there is a remarkable increase in weight against the late phases, which endorses the quality and potential of our health system and Spanish research staff.It also shows the solid commitment of the pharmaceutical industry for collaboration with Spanish centers and health professionals, and points the great development opportunities in this area for our country.
From Farmaindustria they have also pointed out that "one more year, the survey confirms the importance of the biotechnology research for the pharmaceutical industry, since the investment in 2015 in this field increased by more than 12.5 percent withcompared to 2014, reaching 252 million euros.Pharmaceutical in Spain. "
